CDT (CDT Equity) Shareholder Yield % : -592.41% (As of Dec. 2025)


CDT CDT Equity Inc CDT
10 GF Score
Price $0.64
! 5 Warning Signs
View Full Analysis

What is CDT Equity Shareholder Yield %?

CDT Equity CDT -10.81% 10 Shareholder Yield % is -592.41% as of Dec. 2025. GuruFocus rates CDT with a GF Score™ of 10/100. The stock has 5 warning signs investors should review. Among 1,301 Biotechnology companies, CDT Equity ranks worse than 98.16% on this metric.

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, CDT Equity's Shareholder Yield % was -592.41%.


CDT Equity  (NAS:CDT) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


CDT Equity Shareholder Yield % Related Terms


CDT Equity Shareholder Yield % Historical Data

* Premium members only.

The historical data trend for CDT Equity's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CDT Equity Shareholder Yield % Chart

CDT Equity Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Shareholder Yield %
0.00 0.00 0.00 0.00 -622.19

CDT Equity Quarterly Data
Dec21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Shareholder Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -149.93 -218.50 -286.34 -622.19

CDT vs PULM, ADIL, MBIO: Shareholder Yield % Comparison

For the Biotechnology subindustry, CDT Equity's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CDT Equity Shareholder Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CDT Equity's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where CDT Equity's Shareholder Yield % falls into.


CDT
10GF Score
CDT Equity Inc CDT
Shareholder Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CDT Equity Shareholder Yield % Calculation

CDT Equity's Shareholder Yield % for the quarter that ended in Dec. 2025 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0.00 %+-665.52 %+43.33 %
=-622.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.

Frequently Asked Questions Learn more about Shareholder Yield % →
What does a Shareholder Yield % of -592.41% mean?
CDT Equity (CDT) has a Shareholder Yield % of -592.41% as of Dec. 2025. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on CDT Equity and its competitors. According to the industry distribution chart, CDT Equity ranks #1277 out of 1301 companies in the Biotechnology industry, placing it in the top 98.2%.
Is CDT Equity's Shareholder Yield % too high?
CDT Equity's current Shareholder Yield % is -592.41%. Based on the distribution chart, CDT Equity ranks #1277 out of 1301 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CDT Equity has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does CDT Equity's Shareholder Yield % compare to PULM and ADIL?
According to the Biotechnology industry distribution chart, CDT Equity ranks #1277 out of 1301 companies for Shareholder Yield %. This places CDT Equity in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Biotechnology company?
A good Shareholder Yield % depends on the Biotechnology industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on CDT Equity and its competitors. CDT Equity's current Shareholder Yield % is -592.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CDT Equity stock overvalued right now?
CDT Equity (CDT) has a current Shareholder Yield % of -592.41%. The current Shareholder Yield % is -592.41%. CDT Equity's overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For CDT Equity (CDT), the current Shareholder Yield % is -592.41% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CDT Equity Business Description

Address 4581 Tamiami Trail North, Suite 200, Naples, FL, USA, 34103
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.
10GF Score

Get the complete analysis for CDT

Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.64
Price